Table 4.
Characteristics of Impella support. Data are reported as median (interquartile range) or number (percentage), as appropriate.
| Total population (n = 59) | Recovery (n = 21) | No recovery (38) | p-value | |
|---|---|---|---|---|
| Impella 5.0/5.5 support, days (IQR) | 13 (8–20) | 8 (12–15) | 14 (8–24) | 0.4 |
| Mobilization with Impella, n (%) | 23 (36) | 11 (53) | 12 (29) | 0.1 |
| Inotropes during Impella 5.0/5.5, days | 7 (2–16) | 5 (2–11) | 8 (2–18) | 0.9 |
| Weaning from inotropes within 72 h from Impella 5.0/5.5 implant, n | 15 (27%) | 6 (29) | 9 (26) | 0.7 |
| MV during Impella 5.0/5.5, days (IQR) | 7 (3–14) | 6 (1–9) | 12 (5–17) | 0.8 |
| LV function improvement within 7–10 days after implant, n (%) | 21 (36) | 15 (71) | 6 (16) | <0.001 |
| NT-proBNP improving trend within 7–10 days after implant, n (%) | 33 (56%) | 11 (53%) | 22 (58%) | 0.7 |
| Creatinine peak, mg/dl | 3 (1.8–4.5) | 2.3 (1.3–3.6) | 3.2 (1.9–4.5) | 0.1 |
| Renal replacement therapy post Impella 5.0/5.5, n (%) | 22 (36) | 4 (19) | 18 (47) | 0.048 |
| Bilirubin peak, mg/dl | 2 (1.5–4.2) | 1.8 (1.6–2.5) | 3.2 (1.6–5.3) | 0.05 |
| CytoSorb, n (%) | 28 (50) | 9 (43) | 19 (50) | 0.6 |
VA-ECMO, venoarterial ECMO; MV, mechanical ventilation.